Rusfertide and the hepcidin mimetics: a peptide for polycythemia vera
Last updated: October 27, 2026 · 9 min read · By the Grey Peptides Editorial Board
- FDA approved rusfertide (Mimrylo) on August 28, 2026 for erythrocytosis, too many red blood cells, in adults with polycythemia vera 6 3.
- It mimics hepcidin, the hormone that controls iron, reducing the iron available for making red cells 3.
- In its phase 3 trial, 76.9% of patients avoided the need for blood-letting in the assessment window, against 32.9% on placebo 3.
- It raises platelet counts in many patients, so blood counts are monitored closely, and whether it reduces clots has not been shown 3 4.
Polycythemia vera and why blood-letting has been the mainstay
Polycythemia vera is a blood cancer, a myeloproliferative neoplasm, characterised by erythrocytosis, too many red cells 1. It carries a raised risk of thrombosis, and phlebotomy, removing blood, lowers the haematocrit (the share of blood made up of red cells) and with it the incidence of thrombosis 2; the rusfertide label titrates to keep haematocrit below 45% 3. Patients in the REVIVE trial had averaged 8.7 phlebotomies a year before treatment 1. A 2026 review notes that although the disease is driven by constant JAK2 signalling, red-cell overproduction still depends on iron availability, which is the rationale for targeting iron (review) 4.
Treatment choices are built around each patient's thrombosis risk, and phlebotomy is commonly recommended for patients in every risk group; repeated phlebotomy can worsen the iron deficiency many patients already have, with fatigue among its symptoms 2.
How a hepcidin mimetic works
Hepcidin is the body's master iron-regulatory hormone 1. Rusfertide is a synthetic cyclic peptide that mimics it 3. Its label explains that it blocks ferroportin, and that this reduces the iron available for making red cells, lowering haematocrit (drug label) 3. In healthy volunteers, serum iron fell most 24 to 48 hours after a dose, with higher doses keeping it down for up to 96 hours 3.
The effect is a controlled iron restriction aimed at red-cell production, maintained by weekly dosing and adjusted to each patient's haematocrit 3. Iron stores rise rather than fall: in the phase 3 trial, average ferritin rose from 21 mcg/L at baseline to 124 mcg/L at week 32 and 174 mcg/L at week 52 3.
Iron deficiency: the hidden cost of phlebotomy
There is a further reason iron-directed treatment interests haematologists. A 2024 review notes that people with polycythemia vera often already have iron deficiency at diagnosis, because their marrow uses so much iron, and that repeated phlebotomy can worsen it, producing fatigue, lethargy and poor concentration; it describes rusfertide as controlling haematocrit without requiring phlebotomy (review) 2. By restricting iron's use for red cells rather than removing iron from the body, a hepcidin mimetic lets stores recover, which the ferritin rise in VERIFY reflects 3. On fatigue, the label reports a modest difference at week 32 on the PROMIS Fatigue score, 1.98 points lower with rusfertide than placebo (95% CI 0.25 to 3.71), with data for 120 and 115 patients 3.
The approval, as of October 27, 2026
Takeda announced FDA approval of Mimrylo on August 28, 2026, for erythrocytosis in adults with polycythemia vera 5. Drugs@FDA lists it as NDA 220605, a priority review 6. The label sets a starting dose of 19 mg by injection under the skin once a week, adjusted for efficacy or safety within a range of 9.5 to 108 mg weekly; its half-life is about 28.6 hours (drug label) 3. Takeda's release says Protagonist Therapeutics discovered rusfertide and led its development through phase 3, and that Takeda now holds exclusive global development and commercialisation rights 5.
What the VERIFY trial showed
VERIFY was a randomised, double-blind, placebo-controlled phase 3 trial in 293 adults with polycythemia vera who needed frequent phlebotomy, at least three in 28 weeks or five in a year, despite standard care, which included phlebotomy alone or with marrow-suppressing drugs. Patients took rusfertide or placebo on top of their existing treatment for 32 weeks. A responder was someone who did not become eligible for phlebotomy between weeks 20 and 32 (drug label) 3.
| VERIFY outcome (weeks 0 to 32) | Placebo (n=146) | Rusfertide (n=147) |
|---|---|---|
| Responders: no phlebotomy eligibility, weeks 20 to 32 | 32.9% | 76.9% |
| Mean phlebotomies, baseline to week 32 | 1.82 | 0.53 |
Responders made up 76.9% of the rusfertide group against 32.9% on placebo, and the mean number of phlebotomies from baseline to week 32 fell to 0.53 against 1.82 (randomised trial, as reported in the label) 3. Earlier, in the phase 2 REVIVE trial, funded by Protagonist, patients who had averaged 8.7 phlebotomies a year before treatment needed 0.6 a year during rusfertide dose-finding, and in the randomised withdrawal part 60% of those kept on rusfertide responded against 17% switched to placebo (randomised trial) 1.
Who was in the trial
VERIFY's participants had a mean age of 57, ranging from 27 to 86; 73% were men and 89% were White. At randomisation, 44.7% were on phlebotomy alone, 38.9% on phlebotomy plus hydroxyurea, 13.3% on phlebotomy plus interferon and 2.4% on phlebotomy plus ruxolitinib. About half, 46.8%, were classed as high risk, aged 60 or over or with a past clot (drug label) 3. Patients who completed 32 weeks could continue on open-label rusfertide to week 52 and into a long-term extension to week 156 3. That breadth of background treatment matters: rusfertide was added to existing care, not used in place of it, so the results describe its effect on top of standard therapy.
How it is given
The label describes weekly injections under the skin, starting at 19 mg and titrated to keep haematocrit below 45%, within a 9.5 to 108 mg weekly range; doses above 54 mg need two injections and doses above 82 mg are given on separate days (drug label) 3. Rusfertide is broken down into smaller peptides by two pathways, and two active metabolites account for a meaningful share of exposure at steady state 3. A thorough QT study in healthy adults by Protagonist authors, given 90 mg alongside placebo and moxifloxacin controls, found no clinically relevant effect on heart rate or cardiac conduction, with changes in the corrected QT interval closely following placebo (randomised crossover study) 7.
Side effects and warnings
The label lists three warnings. Platelets can rise: within four weeks of starting, platelet counts rose by an average of 31%, 36% of patients exceeded 600 x10^9/L and 6% exceeded 1,000 x10^9/L, usually plateauing by week 8, and 1% stopped because of high platelets; the label advises complete blood counts every 2 to 4 weeks after starting and during dose changes. Injection-site reactions are common, and the label suggests ice, topical corticosteroids, antihistamines or painkillers as needed. Based on animal data, it can harm a fetus, so effective contraception is advised (drug label) 3. The most common adverse reactions in the trial were injection-site reactions in 56% and anaemia in 16% 3.
The platelet rise matters in a disease where clotting is the main danger, which is why monitoring is built into the label.
What it does not yet prove
VERIFY's endpoints were haematocrit control and phlebotomy, which are surrogate markers. The 2026 review points out that current evidence rests largely on surrogate haematological endpoints, and that whether iron-directed treatment reduces thrombotic risk or changes the course of the disease remains undefined (review) 4. In other words, rusfertide is proven to keep haematocrit down without frequent blood-letting; it is not yet proven to prevent strokes or heart attacks, or to slow the cancer itself, which drugs aimed at the malignant clone attempt.
Where it fits among polycythemia vera treatments
The treatments already used in polycythemia vera, such as hydroxyurea, interferon and ruxolitinib, act on the overactive marrow or its signalling; VERIFY enrolled patients taking each of them 3. Rusfertide works differently, by controlling the iron supply rather than the malignant cells. The 2026 review frames targeting the hepcidin-ferroportin axis as a complementary approach to therapies aimed at the disease clone, not a replacement for them (review) 4. In practice that means a haematologist will weigh it as an addition for patients who still need frequent phlebotomy, which is exactly who VERIFY studied, rather than as a stand-alone answer to the disease.
The trial also measured fatigue with a standard patient questionnaire, PROMIS Fatigue Short Form 8a, because fatigue is a major complaint in the disease 3; patients and doctors will want to see how those results hold up over longer follow-up.
Beyond polycythemia vera
Because it controls iron, rusfertide has been studied in other conditions. In an open-label, Protagonist-funded phase 2 trial in hereditary haemochromatosis, 16 adults on maintenance phlebotomy received weekly rusfertide with the aim of keeping transferrin saturation under 40%; mean phlebotomies fell from 2.31 in the 24 weeks before to 0.06 during treatment (open-label trial) 8. In a study with Protagonist authors in 20 patients with poorly controlled polycythemia vera, 85% had a haematocrit below 45% by week 8 and none needed phlebotomy during treatment (open-label study) 9. These are not approved uses. Protagonist has also announced an oral hepcidin-mimetic candidate, though it is early-stage 10.
A designed peptide, not a research peptide
Rusfertide is a good example of what a modern peptide drug looks like: a molecule designed to copy a natural hormone, tested in placebo-controlled trials, and approved with a label that spells out monitoring. Another oral peptide drug with Protagonist roots, icotrokinra (Icotyde, for plaque psoriasis), was jointly discovered by Protagonist and Johnson & Johnson scientists, licensed to Janssen, and approved on March 17, 2026 10 6. Research peptides sold online have no approved label; our guide to 'research use only' explains the difference, and our guide to how peptides are made covers quality.
Questions to ask a haematologist
- How often do I currently need phlebotomy, and would rusfertide reduce that?
- How will my platelets and blood counts be monitored, and what would change the plan?
- Should I continue my current marrow-suppressing treatment alongside it?
- What do we know about clot risk on rusfertide compared with phlebotomy?
- What contraception is needed, and for how long after stopping?
The bottom line
Rusfertide, approved as Mimrylo in August 2026, gives polycythemia vera patients a way to control red-cell counts by restricting iron, mimicking the body's own hepcidin. In its phase 3 trial it greatly reduced the need for blood-letting. It raises platelets in many patients and needs regular blood counts, and it has not yet been shown to prevent clots or change the disease itself. For a condition long managed by draining blood, it is a genuinely new tool.
Frequently asked questions
Is rusfertide FDA-approved?
Yes. FDA approved it as Mimrylo on August 28, 2026, for the treatment of erythrocytosis in adults with polycythemia vera.
How does rusfertide work?
It mimics hepcidin, the iron-control hormone, by blocking the iron transporter ferroportin. That reduces the iron available for making red blood cells, lowering haematocrit.
How well did rusfertide work in trials?
In the phase 3 VERIFY trial, 76.9% of patients on rusfertide avoided phlebotomy eligibility in weeks 20 to 32, against 32.9% on placebo.
What are rusfertide's side effects?
The most common were injection-site reactions (56%) and anaemia (16%). Platelet counts rose in many patients, so blood counts are checked every 2 to 4 weeks after starting.
Does rusfertide prevent blood clots?
Not shown. Its trials measured haematocrit control and phlebotomy; a 2026 review notes that effects on thrombotic risk remain undefined.
Related on Grey Peptides
Sources
- Kremyanskaya, M., et al. (2024). Rusfertide, a Hepcidin Mimetic, for Control of Erythrocytosis in Polycythemia Vera. N Engl J Med, 390(8), 723-735. PMID: 38381675
- Edahiro, Y., et al. (2025). Iron deficiency and phlebotomy in patients with polycythemia vera. Int J Hematol, 121(1), 39-44. PMID: 39528901
- Takeda Pharmaceuticals America. MIMRYLO (rusfertide) US prescribing information: Indications and Usage, Dosage and Administration, Warnings and Precautions 5.1-5.3, Adverse Reactions, Description, Clinical Pharmacology 12.1-12.3, Clinical Studies (VERIFY, NCT05210790). DailyMed set 101aff01-31ed-4841-a8b6-0a5a8503189b, version 2, effective August 28, 2026; read October 3, re-read October 27, 2026. DailyMed
- Costa, A., et al. (2026). Targeting the hepcidin-ferroportin axis in polycythemia vera: a complementary approach to clone-directed therapies. Blood Rev, , 101420. PMID: 42660705
- Takeda (the manufacturer). FDA Approves MIMRYLO (rusfertide) for Polycythemia Vera. News release, August 28, 2026. Read October 3, re-read October 27, 2026. Cited without a link.
- US FDA. Drugs@FDA via openFDA: NDA220605 (Mimrylo, Takeda), original approval August 28, 2026, priority review; NDA220149 (Icotyde, Janssen Biotech), original approval March 17, 2026. Read October 27, 2026.
- Modi, N. B., et al. (2025). Evaluation of Rusfertide, a Hepcidin Mimetic, on Cardiac Repolarization: A Randomized, Placebo- and Positive-Controlled Crossover Thorough QT Study in Healthy Participants. Clin Ther, 47(11), 1043-1052. PMID: 41033871
- Kowdley, K. V., et al. (2023). Rusfertide for the treatment of iron overload in HFE-related haemochromatosis: an open-label, multicentre, proof-of-concept phase 2 trial. Lancet Gastroenterol Hepatol, 8(12), 1118-1128. PMID: 37863080
- Chew, L. P., et al. (2025). Rusfertide rapidly decreases hematocrit in patients with suboptimally controlled polycythemia vera. Leuk Res, 159, 108132. PMID: 41175501
- Protagonist Therapeutics (the developer). Fourth quarter and full year 2025 results (Form 8-K Exhibit 99.1, SEC EDGAR, February 25, 2026): PN-8047, an oral hepcidin functional mimetic; Icotyde jointly discovered by Protagonist and Johnson & Johnson scientists and licensed to Janssen Biotech. Read October 3, re-read October 27, 2026. Cited without a link.
Educational information, not medical advice. Each dose in this guide names its source, an approved label or a published study. None is a recommendation for you. An unapproved compound has no established safe or effective human dose, and products sold for “research use only” are not made or tested for people. Talk to a doctor before acting on anything on this site, including before you start, stop or change any medicine or dose.
New guides and rule changes, by email
One short email when a peptide's legal status moves — an FDA or PCAC decision, a WADA list change, an enforcement action — plus new guides and tools. At most one a week, and none when nothing changes. The newsletter has not started sending yet: your first email will be its first issue.
We keep your email address and the page you signed up from, nothing else. How it works · Privacy · RSS instead